On December 28, 2017, the U.S. Food and Drug Administration (FDA) permitted the marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.
Read more via Fda.gov.
FDA permits marketing of new device for treating diabetic foot ulcers
Share
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
